Brind.
  1. Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.

Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.

1 report, 1 independent Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.

Who's involved

What this event is mainly about
Hoffmann-La RocheHalozyme TherapeuticsBristol-Myers Squibb

Keep exploring

Part of

Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped